BPC-157 vs PDA
Both BPC-157 and PDA are used for recovery. Here's how their evidence, dosing, and regulatory status actually compare.
BPC-157
Evidence B+Body Protection Compound-157
A 15-amino-acid peptide derived from gastric juice. The most popular recovery peptide with 100+ preclinical studies showing accelerated healing of tendons, ligaments, muscle, gut lining, and nerves.
View full BPC-157 profile →PDA
Evidence C+Pentadeca Arginate (PDA)
A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.
View full PDA profile →Side-by-Side
| Attribute | BPC-157 | PDA |
|---|---|---|
| Evidence Grade | B+ | C+ |
| FDA Status | Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026) | Not FDA-approved — newer compounded analog of BPC-157 |
| Typical Dose | 250–500 mcg twice daily (subcutaneous) | 200–500 mcg daily (subcutaneous) |
| Clinics Indexed | 308 | 41 |
| Categories | recovery, gut-health | recovery, anti-inflammatory |
Key reported benefits — BPC-157
- ✓Tendon & ligament repair
- ✓Gut healing
- ✓Muscle recovery
- ✓Neuroprotection
Key reported benefits — PDA
- ✓Tissue repair
- ✓Anti-inflammation
- ✓Potentially better stability than BPC-157
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.